Cimzia (certolizumab pegol) / Astellas, UCB 
Welcome,         Profile    Billing    Logout  
 50 Diseases   29 Trials   29 Trials   3299 News 


«12...1718192021222324252627...3839»
  • ||||||||||  Clinical, Journal:  Biological therapy in genital psoriasis in women. (Pubmed Central) -  Nov 21, 2020   
    Overall, 25/74 (34%) had GenPs: 6 received Ixekizumab, 7 Ustekinumab, 8 Adalimumab, 2 Secukinumab, 1 Etanercept, 1 Certolizumab. No abstract available
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Biomarker, Trial completion date, Trial primary completion date:  RAFTING: Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation (clinicaltrials.gov) -  Nov 13, 2020   
    P4,  N=208, Recruiting, 
    sponsored by UCB (non-CME) Trial completion date: Oct 2021 --> Dec 2023 | Trial primary completion date: Oct 2020 --> Dec 2021
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    Biomarker, Journal:  Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. (Pubmed Central) -  Nov 12, 2020   
    Anti-TNF therapy may act inversely on DKK-1 and SOST. Independent predictors of BMD were SOST and βCTX in RA, whilst CRP in AS.Key Points• One-year anti-TNF therapy halted generalized bone loss in association with clinical improvement in arthritides.• Anti-TNF therapy may inversely act on DKK-1 and SOST.• Independent predictors of BMD were SOST and βCTX in RA, while CRP in AS.
  • ||||||||||  [VIRTUAL] T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster () -  Nov 11, 2020 - Abstract #ACRARHP2020ACR_ARHP_3195;    
    This phenomenon is very likely mediated by type 1 interferon signals and CD96/PVRIG co-inhibition. Elucidating the mechanism mediating the unique effect of adalimumab very likely will uncover novel mechanisms of action of TNFis and improve their efficacy and safety.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    [VIRTUAL] New case paradoxical reactions under tnf-α blocking agents () -  Nov 9, 2020 - Abstract #ECP2020ECP_4447;    
    Methods Under the care there were 2 patients with a diagnosis “Psoriasis Vulgaris, psoriatic arthritis” received therapy with the certolizumab pegol...Conclusion There are different theories that have been proposed to explain PAEs, the most realistic hypothesis is an imbalance in cytokine production, which can contribute to the development of new pathological pathways and cause PAEs. The onset of PAEs close surveillance of newly available biological drugs is necessary in order to detect the occurrence of new and/or undescribed PAEs.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    [VIRTUAL] New case paradoxical reactions under tnf-α blocking agents () -  Nov 9, 2020 - Abstract #ECP2020ECP_2753;    
    Methods Under the care there were 2 patients with a diagnosis “Psoriasis Vulgaris, psoriatic arthritis” received therapy with the certolizumab pegol...Conclusion There are different theories that have been proposed to explain PAEs, the most realistic hypothesis is an imbalance in cytokine production, which can contribute to the development of new pathological pathways and cause PAEs. The onset of PAEs close surveillance of newly available biological drugs is necessary in order to detect the occurrence of new and/or undescribed PAEs.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    [VIRTUAL] New case paradoxical reactions under tnf-α blocking agents () -  Nov 9, 2020 - Abstract #ECP2020ECP_1079;    
    Methods Under the care there were 2 patients with a diagnosis “Psoriasis Vulgaris, psoriatic arthritis” received therapy with the certolizumab pegol...Conclusion There are different theories that have been proposed to explain PAEs, the most realistic hypothesis is an imbalance in cytokine production, which can contribute to the development of new pathological pathways and cause PAEs. The onset of PAEs close surveillance of newly available biological drugs is necessary in order to detect the occurrence of new and/or undescribed PAEs.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    Journal:  The Laboratory Role in anti-TNF Biological Therapy Era. (Pubmed Central) -  Nov 7, 2020   
    A raising number of diagnostic tests have been designed to elucidate the efficacy and/or safety of a specific drug or class of drugs for a targeted patient's group. Our paper reviewed the current understanding of the immunogenicity of biological drugs employed in the treatment of inflammatory diseases underlying the laboratory role.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion date, Trial primary completion date:  IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy (clinicaltrials.gov) -  Nov 4, 2020   
    P2,  N=50, Recruiting, 
    Our paper reviewed the current understanding of the immunogenicity of biological drugs employed in the treatment of inflammatory diseases underlying the laboratory role. Trial completion date: May 2021 --> Nov 2022 | Trial primary completion date: May 2020 --> Nov 2022
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Enrollment open:  Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) -  Oct 19, 2020   
    P3,  N=193, Recruiting, 
    Still, we need more studies to make biological therapy as a first option in the treatment of inflammatory bowel disease. Active, not recruiting --> Recruiting
  • ||||||||||  [VIRTUAL] Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines () -  Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2071;    
    This phenomenon is very likely mediated by type 1 interferon signals and CD96/PVRIG co-inhibition. Elucidating the mechanism mediating the unique effect of adalimumab very likely will uncover novel mechanisms of action of TNFis and improve their efficacy and safety.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    [VIRTUAL] Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients () -  Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_1882;    
    Background/Purpose: Infliximab and adalimumab therapy has significantly improved the prognosis of patients with non-infectious refractory uveitis...Previous CZP, patients received: oral prednisone (n=18) methylprednisolone bolus (1), methotrexate (22), azathioprine (10), cyclosporine (4), leflunomide (2), mycophenolate mofetil (2) and cyclophosphamide (1)... CZP seems to be effective and safe in patients with refractory uveitis due to IMID.
  • ||||||||||  [VIRTUAL] Risk of Non-vertebral Fractures Among Rheumatoid Arthritis Patients Treated with Biologic or Targeted-Synthetic DMARDs: A Multi-Database Comparative Safety Study () -  Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_1635;    
    The primary objective of this study was to compare the incidence rate of NVFs in RA patients initiating one of the 9 b/tsDMARDs: abatacept (ABA), adalimumab (ADA), certolizumab (CER), etanercept (ETA), golimumab (GOL), infliximab (INF), rituximab (RIT), tocilizumab (TCZ) or tofacitinib (TOF)...During the 365-day baseline period, 39-65% patients used methotrexate, 64-71% used corticosteroids, and 13-30% had osteoporosis... This large multi-database cohort study of RA patients found no differences in the risk of composite endpoint of NVFs or specific NVFs after starting ABA, CER, ETA, GOL, INF, RIT, TCZ or TOF versus starting ADA as their first or second b/tsDMARD therapy.